Ann D. Rhoads - 05 May 2021 Form 4 Insider Report for Evoke Pharma Inc (EVOK)

Reporting relationship: Director
Issuer ticker: EVOK
Reported as of: 05 May 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jul 2021, 18:26:11 UTC
Next SEC filing: 14 May 2021
Source filing: View source filing
Reporting owner signature: /s/ Matthew J. D'Onofrio, Attorney-in-fact for Ann D. Rhoads

Key filing fact

Ann D. Rhoads filed Form 4 for Evoke Pharma Inc (EVOK) on 23 Jul 2021.

Key facts

This page summarizes Ann D. Rhoads's Form 4 filing for Evoke Pharma Inc (EVOK).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Jul 2021, 18:26.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EVOK transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +61,750
Change %
Price: $0.000000
Shares after: 61,750
Date: 05 May 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 61,750
Exercise price: $1.55
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the reporting person's continued service to the Issuer through such vesting date.